Switch theme
Sign up to access all valuation multiples
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
2009
41
LTM Revenue $2.5M
LTM EBITDA -$60.6M
-$90.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Contineum Therapeutics has a last 12-month revenue (LTM) of $2.5M and a last 12-month EBITDA of -$60.6M.
In the most recent fiscal year, Contineum Therapeutics achieved revenue of n/a and an EBITDA of -$42.0M.
Contineum Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Contineum Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $2.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$60.6M | XXX | -$42.0M | XXX | XXX | XXX |
| EBITDA Margin | -2441% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$60.0M | XXX | -$50.9M | XXX | XXX | XXX |
| EBIT Margin | -2417% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$51.5M | XXX | -$42.3M | XXX | XXX | XXX |
| Net Margin | -2076% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Contineum Therapeutics's stock price is $4.
Contineum Therapeutics has current market cap of $94.7M, and EV of -$90.0M.
See Contineum Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$90.0M | $94.7M | XXX | XXX | XXX | XXX | $-2.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Contineum Therapeutics has market cap of $94.7M and EV of -$90.0M.
Contineum Therapeutics's trades at -1.8x EV/Revenue multiple, and 2.1x EV/EBITDA.
Equity research analysts estimate Contineum Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Contineum Therapeutics has a P/E ratio of -1.8x.
See valuation multiples for Contineum Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $94.7M | XXX | $94.7M | XXX | XXX | XXX |
| EV (current) | -$90.0M | XXX | -$90.0M | XXX | XXX | XXX |
| EV/Revenue | -36.3x | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBITDA | 1.5x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBIT | 1.5x | XXX | 1.8x | XXX | XXX | XXX |
| EV/Gross Profit | -36.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.8x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 2.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialContineum Therapeutics's last 12 month revenue growth is 42%
Contineum Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
Contineum Therapeutics's rule of 40 is 89% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Contineum Therapeutics's rule of X is -2336% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Contineum Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -2441% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 50% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 89% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2336% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Contineum Therapeutics acquired XXX companies to date.
Last acquisition by Contineum Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Contineum Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Contineum Therapeutics founded? | Contineum Therapeutics was founded in 2009. |
| Where is Contineum Therapeutics headquartered? | Contineum Therapeutics is headquartered in United States of America. |
| How many employees does Contineum Therapeutics have? | As of today, Contineum Therapeutics has 41 employees. |
| Who is the CEO of Contineum Therapeutics? | Contineum Therapeutics's CEO is Mr. Carmine Stengone. |
| Is Contineum Therapeutics publicy listed? | Yes, Contineum Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Contineum Therapeutics? | Contineum Therapeutics trades under CTNM ticker. |
| When did Contineum Therapeutics go public? | Contineum Therapeutics went public in 2024. |
| Who are competitors of Contineum Therapeutics? | Similar companies to Contineum Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Contineum Therapeutics? | Contineum Therapeutics's current market cap is $94.7M |
| What is the current revenue of Contineum Therapeutics? | Contineum Therapeutics's last 12 months revenue is $2.5M. |
| What is the current revenue growth of Contineum Therapeutics? | Contineum Therapeutics revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Contineum Therapeutics? | Current revenue multiple of Contineum Therapeutics is -36.3x. |
| Is Contineum Therapeutics profitable? | Yes, Contineum Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Contineum Therapeutics? | Contineum Therapeutics's last 12 months EBITDA is -$60.6M. |
| What is Contineum Therapeutics's EBITDA margin? | Contineum Therapeutics's last 12 months EBITDA margin is -2441%. |
| What is the current EV/EBITDA multiple of Contineum Therapeutics? | Current EBITDA multiple of Contineum Therapeutics is 1.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
